Blake Erin A, Ross Megan, Ihenacho Ugonna, Figueroa Lizzette, Silverstein Emily, Flink Dina, Mendez-Ishizaki Yumi, Yessaian Annie, Brunette Laurie L, Matsuo Koji, Cortessis Victoria K, Guntupalli Saketh, Roman Lynda
Division of Gynecologic Oncology, Department of Obstetrics and Gynecologic, University of Southern California, Los Angeles, CA, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Denver, CO, USA.
Gynecol Oncol Rep. 2019 Sep 9;30:100497. doi: 10.1016/j.gore.2019.100497. eCollection 2019 Nov.
To evaluate interest in and patterns of use of non-prescription cannabis products for symptom management amongst gynecologic cancer patients living in states with legal access to medical and recreational marijuana.
Cross-sectional study using a novel 35-question survey distributed to women diagnosed with gynecologic cancer within two academic centers in California and Colorado. The survey queries demographic and disease traits, and both objective and subjective issues surrounding use of cannabis products for symptom management. Surveys were distributed to patients actively receiving treatment or under surveillance.
Enrollment began July 16, 2018 and was completed December 1, 2018. Survey return rate was 52.7%. A total of 225 participants met inclusion criteria.Sixty-two percent reported that they have used or would be interested in using cannabis products for symptom management; 60 (26.7%) are using non-prescription cannabis for treatment of cancer related symptoms, and 80 (35.6%) are interested in using cannabis derivatives under direction of their oncologist. Reasons cited for use of cannabis included: pain control (n = 41, 68.3), insomnia (n = 33, 55.0%), anxiety (n = 29, 48.3%), nausea (n = 26, 43.3%), and appetite stimulation (n = 21, 35.0%). Of the women using cannabis products, almost half report decreased prescription narcotic use after initiation of cannabis products (n = 27, 45.0%).
Women with gynecologic cancer report a strong interest in the use of non-prescription cannabis products for management of cancer-related symptoms. Practitioners in the field of gynecologic oncology should be aware of the frequency of use of non-prescription cannabis amongst their patients as well as the growing desire for guidance about the use of cannabis derivatives. A substantial number of patients report decreased reliance on opioids when using cannabis derivatives for pain control.
评估在合法获取医用和娱乐用大麻的州，妇科癌症患者对非处方大麻产品用于症状管理的兴趣及使用模式。
采用一项新的包含35个问题的调查问卷进行横断面研究，该问卷分发给在加利福尼亚州和科罗拉多州的两个学术中心被诊断为妇科癌症的女性。该调查询问人口统计学和疾病特征，以及围绕使用大麻产品进行症状管理的客观和主观问题。调查问卷分发给正在积极接受治疗或处于监测中的患者。
招募工作于2018年7月16日开始，并于2018年12月1日完成。调查回复率为52.7%。共有225名参与者符合纳入标准。62%的人报告称他们已经使用或有兴趣使用大麻产品进行症状管理；60人（26.7%）正在使用非处方大麻治疗癌症相关症状，80人（35.6%）有兴趣在肿瘤学家的指导下使用大麻衍生物。使用大麻的原因包括：控制疼痛（n = 41，68.3%）、失眠（n = 33，55.0%）、焦虑（n = 29，48.3%）、恶心（n = 26，43.3%）和刺激食欲（n = 21，35.0%）。在使用大麻产品的女性中，近一半报告在开始使用大麻产品后处方麻醉药品的使用量减少（n = 27，45.0%）。
患有妇科癌症的女性对使用非处方大麻产品管理癌症相关症状表现出浓厚兴趣。妇科肿瘤学领域的从业者应了解患者中非处方大麻的使用频率，以及对大麻衍生物使用指导的需求日益增长。相当数量的患者报告在使用大麻衍生物控制疼痛时对阿片类药物的依赖减少。
